
Aeva (AEVA) Q2 Revenue Jumps 175%
Revenue (GAAP) surged to $5.5 million, up from $2.0 million in Q2 2024, far outpacing the GAAP consensus estimate of $3.39 million.
Non-GAAP net loss per share improved to $(0.44), beating the $(0.47) non-GAAP EPS expected by analysts.
Cash, cash equivalents, and marketable securities decreased to $49.8 million as of June 30, 2025.
These 10 stocks could mint the next wave of millionaires ›
Aeva Technologies (NASDAQ:AEVA), a Silicon Valley-based developer of 4D LiDAR sensing solutions, reported its financial results for the second quarter of fiscal 2025 on July 31, 2025. Aeva delivered record GAAP revenue of $5.5 million, up 175% year-over-year (GAAP) and well above analyst expectations. Non-GAAP earnings per share came in at $(0.44), also ahead of the consensus non-GAAP estimate of $(0.47). This quarter reflects major commercial and technological progress, but ongoing negative gross margins and significant operating losses remain key watch points.
Metric Q2 2025 Q2 2025 Estimate Q2 2024 Y/Y Change
EPS (Non-GAAP) ($0.44) ($0.47) ($0.57) 22.8%
Revenue $5.5 million $3.39 million $2.0 million 174.6%
Operating Loss (Non-GAAP) ($25.1 million) ($32.0 million) 21.6%
Cash, Cash Equivalents & Marketable Securities $49.8 million N/A N/A
Source: Analyst estimates for the quarter provided by FactSet.
About Aeva Technologies: What It Does and What Matters
Aeva Technologies develops Frequency-Modulated Continuous Wave (FMCW) LiDAR, a sensor technology that helps machines and vehicles perceive and measure their environment with high accuracy. Its main products enable instant velocity detection and 3D spatial measurement, supporting critical applications in autonomous vehicles, robotics, and industrial automation.
The business has recently focused on scaling up its core FMCW technology, integrating it into both automotive and industrial use-cases. Its future depends on the successful commercialization of its unique sensor platform, expansion into new segments like smart infrastructure, and partnerships with manufacturers and major customers. Intellectual property protection and regulatory compliance are also key factors for sustained growth and technology adoption.
Quarter in Detail: Financial and Strategic Progress
This quarter, Aeva set a new high with GAAP revenue of $5.5 million, with GAAP sales more than doubling year over year and surpassing analyst estimates by 62.2% for GAAP revenue. The company attributes this growth to continued commercial momentum, driven in part by strategic collaborations, including a focus on both automotive and industrial sectors.
Operating loss (Non-GAAP) narrowed to $(25.1 million), improving from a $(32.0 million) non-GAAP operating loss in Q2 2024. This reflects the company's efforts to control spending, with research and development expenses decreasing from $26,196,000 in Q2 2024 to $22,841,000, and general and administrative expenses decreasing from $8,663,000 in Q2 2024 to $7,969,000, with reductions reported in research and development and general administrative expenses. However, gross margins remained negative (GAAP): cost of goods sold rose to $8.2 million, outpacing top-line growth due to higher costs tied to early stage scale-up and investments in manufacturing.
A major highlight was the partnership with LG Innotek, which included a $77.5 million strategic investment recognized as a share subscription liability as of June 30, 2025, until closing. This relationship is anticipated to help Aeva broaden its market reach and ramp up manufacturing via expanded volume production. In parallel, the company reported orders for over 1,000 sensors in its industrial automation segment for Q1 2025, with shipments set for later this year, and cited ongoing programs with partners like Mercedes-Benz, Daimler Truck, and Bendix in the automotive space.
Aeva continues to invest in capacity and technological development, but this cash burn underscores ongoing dependence on additional financing. The company maintains a $125 million equity facility to support future needs. Non-cash liabilities, including a $102.1 million warrant liability, have caused volatility in GAAP net income, but these are not expected to impact near-term cash flows. There were no dividends declared or adjusted during the quarter.
How Aeva's Products and Partnerships Matter
The core of Aeva's business is its FMCW LiDAR platform, which underpins its suite of products for the automotive and industrial markets. In automotive, product families like the Atlas Ultra LiDAR sensors are being positioned for advanced driver-assistance systems and autonomous driving, and have gained traction with customers such as Mercedes-Benz and Daimler Truck. In commercial vehicles, partnerships like those with Bendix target large-scale collision mitigation opportunities in heavy truck fleets.
On the industrial side, Aeva has introduced the Eve 1 line of precision laser displacement sensors. These are used for factory process automation and quality control, providing micron-level measurement accuracy—a capability that offers significant benefits for manufacturers. Key partners here include LMI Technologies and SICK AG, both of which have placed significant orders and are among the top companies in their field.
In addition to vehicle and industrial applications, Aeva's technology has begun to see adoption in new segments like airport traffic management and intelligent transportation systems. The company's 4D LiDAR sensors are being deployed for smart traffic and safety enforcement, supporting customers such as D2 Traffic and Sensys Gatso. These applications demonstrate the breadth of Aeva's platform and underscore its potential outside automotive alone.
Strategic manufacturing partnerships with companies such as Tower Semiconductor and Jabil are helping Aeva move towards mass production scale. These partners are supporting the integration of Aeva's chip-based LiDAR technology, aiming for production capacity of up to 100,000 units per year.
Looking Ahead: Expectations and Areas to Watch
This is based on ongoing commercial momentum and booked sensor orders, but it does not yet include the full potential impact of the LG Innotek relationship. No detailed guidance was given for the next quarter, and management signaled that further updates will follow as new business milestones are reached.
Investors should monitor whether Aeva converts pre-production partnerships into large-scale series production, especially in automotive and industrial markets. Cost structure remains a challenge: the company will need to improve gross margins as it moves from development to volume manufacturing. Cash burn and capital sourcing are also critical, given falling reserves and a negative equity position.
Revenue and net income presented using U.S. generally accepted accounting principles (GAAP) unless otherwise noted.
Where to invest $1,000 right now
When our analyst team has a stock tip, it can pay to listen. After all, Stock Advisor's total average return is 1,036%* — a market-crushing outperformance compared to 181% for the S&P 500.
They just revealed what they believe are the 10 best stocks for investors to buy right now, available when you join Stock Advisor.
See the stocks »
*Stock Advisor returns as of July 29, 2025
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Toronto Star
25 minutes ago
- Toronto Star
Quantum Biopharma Reports Strong Second Quarter with Increased Current and Total Assets, Conversion of all Debentures into Equity, Continued Exclusion of Going Concern, Tripling of Share Price during Quarter, over $500,000 USD Gain in Crypto Assets as of date of filing, and Near Elimination of Debt
TORONTO, Aug. 07, 2025 (GLOBE NEWSWIRE) — Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FRA: 0K91) ('Quantum BioPharma' or the 'Company'), is pleased to announce its financial and operational results for the second quarter ending June 30, 2025. Overall, the Company is in a strong position having increased its current and total assets, compared to the previous quarter; eliminated the entire debt liability associated with debentures issued in Q4 2024 and Q1 2025 by converting all debentures into equity; maintained its 'no going concern' status; seen greater than $500,000 USD appreciation in the value of its cryptocurrency reserves as of date of filing; and seen its stock price almost tripled from $7.71 USD at Q1 close March 31, 2025 to $20.25 USD at Q2 close June 30, 2025. Management believes that there is sufficient cash on hand to maintain basic operations beyond March 2027.


Toronto Star
25 minutes ago
- Toronto Star
XORTX Provides Corporate Update and Planned Activities for 2025 / 2026
CALGARY, Alberta, Aug. 07, 2025 (GLOBE NEWSWIRE) — XORTX Therapeutics Inc. ('XORTX' or the 'Company') (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late stage clinical pharmaceutical company focused on developing innovative therapies to treat gout and progressive kidney disease, is pleased to provide a comprehensive update on its 2025 progress and strategic goals for 2026. The first half of 2025 has been marked by intense focus and significant advancement, solidifying a robust plan to accelerate the lead gout program towards a NDA filing, aiming to propel technology toward revenue generation and foster substantial shareholder value.


Cision Canada
25 minutes ago
- Cision Canada
Aurora to Participate in Canaccord Genuity 45th Annual Growth Conference
Canada's Largest Medical Cannabis Company to Discuss Strategy, Industry Trends, and Long-Term Growth Outlook EDMONTON, ALBERTA, Aug. 7, 2025 /CNW/ - Aurora Cannabis Inc. (NASDAQ: ACB) (TSX: ACB), the Canadian-based leading global medical cannabis company, will participate in Canaccord Genuity 45th Annual Growth Conference in Boston, MA. Simona King, Chief Financial Officer at Aurora, will take part in a fireside chat on August 13th at 1:30pm EST and conduct one-on-one meetings with investors throughout the day. The discussion will cover Aurora's strategic direction, recent milestones, and growth opportunities, highlighting the company's commitment to innovation and leadership in the global medical cannabis sector. Conference Call Details To listen to the live audio webcast, please register using the weblink above, which has also been posted to the Company's "Investor Info" section at under "Events". A replay of the presentation will be available using the same link for approximately 90 days. About Aurora Cannabis Inc. Aurora is opening the world to cannabis, serving both the medical and consumer markets across Canada, Europe, Australia and New Zealand. Headquartered in Edmonton, Alberta, Aurora is a pioneer in global cannabis, dedicated to helping people improve their lives. The Company's adult-use brand portfolio includes Drift, San Rafael '71, Daily Special, Tasty's, Being and Greybeard. Medical cannabis brands include MedReleaf, CanniMed, Aurora and Whistler Medical Marijuana Co., as well as international brands, Pedanios, IndiMed and CraftPlant. Aurora also has a controlling interest in Bevo Farms Ltd., North America's leading supplier of propagated agricultural plants. Driven by science and innovation, and with a focus on high-quality cannabis products, Aurora's brands continue to break through as industry leaders in the medical, wellness and adult recreational markets wherever they are launched. Learn more at and follow us on X and LinkedIn. Aurora's common shares trade on the NASDAQ and TSX under the symbol "ACB". Forward Looking Information This news release includes statements containing certain "forward-looking information" within the meaning of applicable securities law ("forward-looking statements"). Forward-looking statements are frequently characterized by words such as "plan", "continue", "expect", "project", "intend", "believe", "anticipate", "estimate", "may", "will", "potential", "proposed" and other similar words, or statements that certain events or conditions "may" or "will" occur. Forward-looking statements made in this news release include, but are not limited to, statements regarding the Company's upcoming participation at the Canaccord Genuity 45 th Annual Growth Conference and topics of discussion. These forward-looking statements are only predictions. Forward looking information or statements contained in this news release have been developed based on assumptions management considers to be reasonable. Material factors or assumptions involved in developing forward-looking statements include, without limitation, publicly available information from governmental sources as well as from market research and industry analysis and on assumptions based on data and knowledge of this industry which the Company believes to be reasonable. Forward-looking statements are subject to a variety of risks, uncertainties and other factors that management believes to be relevant and reasonable in the circumstances could cause actual events, results, level of activity, performance, prospects, opportunities or achievements to differ materially from those projected in the forward-looking statements. These risks include, but are not limited to, the magnitude and duration of potential new or increased tariffs imposed on goods imported from Canada into the United States; the ability to retain key personnel, the ability to continue investing in infrastructure to support growth, the ability to obtain financing on acceptable terms, the continued quality of our products, customer experience and retention, the development of third party government and non-government consumer sales channels, management's estimates of consumer demand in Canada and in jurisdictions where the Company exports, expectations of future results and expenses, the risk of successful integration of acquired business and operations, management's estimation that SG&A will grow only in proportion of revenue growth, the ability to expand and maintain distribution capabilities, the impact of competition, the general impact of financial market conditions, the yield from cannabis growing operations, product demand, changes in prices of required commodities, competition, and the possibility for changes in laws, rules, and regulations in the industry, epidemics, pandemics or other public health crises and other risks, uncertainties and factors set out under the heading "Risk Factors" in the Company's annual information from dated June 17, 2025 (the "AIF") and filed with Canadian securities regulators available on the Company's issuer profile on SEDAR+ at and filed with and available on the SEC's website at The Company cautions that the list of risks, uncertainties and other factors described in the AIF is not exhaustive and other factors could also adversely affect its results. Readers are urged to consider the risks, uncertainties and assumptions carefully in evaluating the forward-looking statements and are cautioned not to place undue reliance on such information. The Company is under no obligation, and expressly disclaims any intention or obligation, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as expressly required by applicable securities law. SOURCE Aurora Cannabis Inc.